ALKBH5 induces macrophage activation to promote renal fibrosis via Retnla

Long Zheng1, Wenjun Gao1, Zhenan Zhang1

  • 1Department of Urology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.

Renal Failure
|June 26, 2025
PubMed

Insights

Researchers identified RNA demethylase ALKBH5 as a key driver in kidney fibrosis. Inhibiting ALKBH5 in macrophages reduces fibrosis by downregulating Retnla, offering a potential therapeutic target for chronic kidney disease.

Area of Science:

  • Nephrology
  • Immunology
  • Molecular Biology

Background:

  • Renal fibrosis is a common outcome of chronic kidney diseases.
  • Macrophages are implicated in renal fibrosis, but their precise role and mechanisms are not fully understood.

Purpose of the Study:

  • To investigate the role of RNA demethylase AlkB Homolog 5 (ALKBH5) in macrophage-mediated renal fibrosis.
  • To elucidate the molecular mechanisms by which ALKBH5 influences kidney fibrosis progression.

Main Methods:

  • Utilized unilateral ureteral obstruction (UUO) mouse models and TGF-β treated bone marrow-derived macrophages.
  • Performed macrophage-specific ALKBH5 knockout experiments.
  • Conducted RNA sequencing to identify downstream targets of ALKBH5.

Main Results:

  • Increased ALKBH5 expression was observed in macrophages during renal fibrosis.
  • Macrophage-specific ALKBH5 knockout ameliorated renal fibrosis and reduced macrophage infiltration.
  • ALKBH5 deficiency suppressed M2a macrophage polarization and key markers (TGF-β1, Arg1, CD206).
  • Resistin-like alpha (Retnla) was identified as a downstream target of ALKBH5, mediating its fibrotic effects.

Conclusions:

  • ALKBH5 promotes renal fibrosis by regulating macrophage polarization and function.
  • The ALKBH5-Retnla axis in macrophages represents a novel therapeutic target for chronic kidney disease and renal fibrosis.